鼠抗卡马西平抗体
货号：grCB101
简介：
鼠抗卡马西平单克隆抗体，Carbamazepine antibody
Carbamazepine was first discovered and developed in Basel, Switzerland, at the labs of J.R. Geigy AG by Schindler and others around 1954. Initially, it was recognized as a treatment for trigeminal neuralgia (Blom 1962). The anticonvulsant properties of carbamazepine were subsequently reported in animals (Theobald and Kunz 1963) and clinical trials in humans (Lustig 1964) in the early 1960s. Since then, numerous trials have demonstrated carbamazepine to be effective in the treatment of partial onset and generalized seizures. Carbamazepine was originally introduced in Switzerland and the UK in 1963 as an antiepileptic medication. In the USA, carbamazepine won initial approval by the FDA for treatment of trigeminal neuralgia in 1968. Approval for use in epilepsy (Tegretol) did not occur until 1974, and was not extended to use in children until several decades later.
产品介绍
其它名称：卡马西平单克隆抗体，Carbamazepine Antibody，Mouse anti Carbamazepine antibody
货号：grCB101
种类：抗体
应用：CLIA ,LETIA
特异性：Carbamazepine
来源：Mouse
存贮：-20℃
产品说明
Carbamazepine was approved as a mood stabilizer in 2004 and has also been shown to be beneficial for psychosis in Alzheimer dementia.3,4Carbamazepine acts primarily as an antiepileptic by blocking voltage gated sodium channels and L-type calcium channels.It also demonstrates antagonism of the anti-NMDA receptor (like valproic acid) but to a lesser extent.
Thought to have mood stabilization properties because of its close structural relationship to imipramine, carbamazepine has been comparable to lithium and haloperidol for mood stabilization in several large trials. The literature also has shown carbamazepine’s utilization for acute agitation.
相关产品
鼠抗卡马西平抗体
货号：grCB101
